About Zydus
Zydus is a Healthcare company. Pharmaceutical products are manufactured and researched by Zydus globally. The company has 13,762 employees. Its Indian entity Zydus Lifesciences Limited reported revenue of ₹13,152 Cr. Zydus offers products and services including Generics for Hepatitis C and Vaccines and Bio-similars. Its focus areas include Biotechnology, Research and Development, Bio-similars and NCEs and Pharmaceuticals.
Company details
Zydus is recognized as a leading Indian pharmaceutical manufacturer that produces generics, vaccines, and bio-similars, with operations spanning multiple countries and a focus on treatments for hepatitis C, oncology, and metabolic diseases. More than 30 production facilities are maintained worldwide, supported by over 23,000 employees and extensive research in 19 centers. Innovative drugs like Lipaglyn TM and Exemptia are developed to address public health needs, while authenticity is ensured through verification processes. Programs for improving access to essential medicines are implemented, emphasizing ethical standards and global contributions in healthcare innovation.
- Employees 13,762
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website zydus.ru
- Legal Name Zydus Lifesciences Ltd
- Date of Incorporation 15 May, 1995
- Jurisdiction Ahmedabad, Gujarat, India
- Indian entity revenue₹13,152 Cr
FY 2026 · +18% YoY
- Indian entity net profit₹5,124 Cr
FY 2026 · 19% margin
- Indian entity EBITDA₹8,565 Cr
FY 2026 · 31% margin
- Employee Count13,762
Associated legal entities of Zydus
Zydus operates through Zydus Lifesciences Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Zydus Lifesciences Limited Listed CIN L24230GJ1995PLC025878 | Active | 15 May 1995 | Ahmedabad, Gujarat | ₹13,152 Cr | 13,762 | 11 | View details |
Products & Services of Zydus
Zydus offers a comprehensive portfolio of products and services, including Generics for Hepatitis C and Vaccines and Bio-similars.
Generics including sofosbuvir are manufactured for hepatitis C treatment
Vaccines such as Vaxiflu S are developed for influenza prevention
Board of directors of Zydus Lifesciences Limited (Zydus)
Zydus Lifesciences Limited is the primary company behind Zydus. The board of Zydus Lifesciences Limited currently have 9 directors; the longest-serving is Pankaj Ramanbhai Patel, appointed in 1995. 10 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Pankaj Ramanbhai Patel DIN 00131852 | Director | 15 May 1995 | 31 yrs 5 mo | Zydus Lifesciences Limited |
| Sharvil Pankajbhai Patel DIN 00131995 | Managing Director | 01 Aug 1997 | 29 yrs 3 mo | Zydus Lifesciences Limited |
| Mukesh Mangalbhai Patel DIN 00053892 | Director | 01 Aug 1997 | 29 yrs 3 mo | Zydus Lifesciences Limited |
| Ganesh Narayan Nayak DIN 00017481 | Director | 12 Jul 2017 | 9 yrs 3 mo | Zydus Lifesciences Limited |
| Bhadresh Kantilal Shah DIN 00058177 | Director | 06 Dec 2018 | 7 yrs 10 mo | Zydus Lifesciences Limited |
| Monappa Arun Akhil DIN 09784366 | Director | 29 Nov 2022 | 3 yrs 11 mo | Zydus Lifesciences Limited |
| Upasana Konidela DIN 02781278 | Director | 29 Nov 2022 | 3 yrs 11 mo | Zydus Lifesciences Limited |
| Shelina Pranav Parikh DIN 00468199 | Director | 17 May 2024 | 2 yrs 5 mo | Zydus Lifesciences Limited |
| Kulin Sanjay Lalbhai DIN 05206878 | Director | 19 May 2026 | 5 mo | Zydus Lifesciences Limited |
Financials of Zydus
Figures of Zydus Lifesciences Limited, the primary company behind Zydus, for FY 2026. Revenue was ₹13,152 Cr (+18% year on year). Net profit was ₹5,124 Cr (19% margin). EBITDA was ₹8,565 Cr (31% margin). Revenue has grown at a compounded annual rate of +16% over three years and +13% over five years.
- ₹13,152 CrRevenue · FY 2026 · +18% YoY
- ₹5,124 CrNet profit · 19% margin
- ₹8,565 CrEBITDA · 31% margin
- ₹99.75 CrPaid-up capital
- 13,762Employees (provident fund records)
- +16%Revenue CAGR, 3 years
- +13%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Zydus Lifesciences Limited are on its company page.
Detailed financial statements for Zydus
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Zydus
Complete news archive for Zydus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zydus
Zydus has 13,762 employees.
The primary company behind Zydus, Zydus Lifesciences Limited, reported revenue of ₹13,152 Cr for FY 2026, up 18% year on year.
Zydus is recognized as a leading Indian pharmaceutical manufacturer that produces generics, vaccines, and bio-similars, with operations spanning multiple countries and a focus on treatments for hepatitis C, oncology, and metabolic diseases. More than 30 production facilities are maintained worldwide, supported by over 23,000 employees and extensive research in 19 centers. Innovative drugs like Lipaglyn TM and Exemptia are developed to address public health needs, while authenticity is ensured through verification processes. Programs for improving access to essential medicines are implemented, emphasizing ethical standards and global contributions in healthcare innovation.
Zydus offers Generics for Hepatitis C and Vaccines and Bio-similars.
Zydus operates through Zydus Lifesciences Limited.
The legal entities of Zydus currently have 11 directors, including Sharvil Pankajbhai Patel, Bhadresh Kantilal Shah, Dhaval Narendra Soni and others.